Suggested remit: To appraise the clinical and cost effectiveness of Beremagene geperpavec within its marketing authorisation for treating skin wounds assocatied with dystrophic epidermolysis bullosa.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- The topic routing was re-considered by the Topic Selection Oversight Panel (TSOP) in September 2023. The panel concluded that the topic should remain routed to the Technology Appraisal (TA) work programme. Please see project documents for further details. The timelines for the evaluation are to be confirmed.
- Process:
- STA Standard
- ID number:
- 3959
Provisional Schedule
- Committee meeting: 2:
- 24 September 2026
- Expected publication:
- 18 November 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email TAteam3@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Krystal Biotech Inc (beremagene geperpavec)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Cure EB
- DEBRA UK
- Gene People
- Professional groups
- British Association of Dermatologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Chiesi (Birch bark extract) CAU received - participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Cell and Gene Therapy Catapult
- Department of Health- Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 May 2026 | Committee meeting: 1 |
| 02 September 2025 | Note - Note added to the project documents |
| 10 February 2025 | Invitation to participate |
| 02 December 2024 - 16 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 02 December 2024 | In progress. We consulted on the draft scope for this appraisal in 2022. The appraisal was paused but is now restarting. To ensure that the scope is up to date we are now holding a short second consultation. |
| 15 January 2024 | Note - Note added to the project documents |
| 11 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 11 January 2024 | Topic selection |
| 28 July 2023 | Note added to the project documents |
| 14 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 June 2023 | Topic selection |
| 14 June 2023 | Topic selection. Routing update |
| 19 January 2023 (14:00) | Scoping workshop |
| 09 November 2022 - 07 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 20 May 2022 | In progress. Scoping commencing |
For further information on our processes and methods, please see our CHTE processes and methods manual